Liquid Biopsy Potential Biomarkers in Prostate Cancer

Neuhaus, Jochen; Yang, Bo

doi:10.3390/diagnostics8040068

Cited by 11 publications

(10 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer is the second most common cancer in men worldwide, with mortality in the fifth position of cancer deaths (Neuhaus and Yang, 2018). Studies show that prostate cancer patients have higher plasma cfDNA levels than healthy individuals, and cfDNA levels may be related to disease stage (Moyer, 2012).…”

Section: Tumors With Higher Quantities Of Ctdna In the Patient´s Bloodmentioning

confidence: 99%

ctDNA as a Cancer Biomarker: A Broad Overview

Pessôa

Heringer²,

Ferrer

2020

Preprint

View full text Add to dashboard Cite

Circulating tumor DNA (ctDNA) in fluids has gained attention because ctDNA seems to identify tumor-specific abnormalities, which could be used for diagnosis, follow-up of treatment, and prognosis: the so-called liquid biopsy. Liquid biopsy is a minimally invasive approach and presents the sum of ctDNA from primary and secondary tumor sites. It has been possible not only to quantify the amount of ctDNA but also to identify (epi)genetic changes. Specific mutations in genes have been identified in the plasma of patients with several types of cancer, which highlights ctDNA as a possible cancer biomarker. However, achieving detectable concentrations of ctDNA in body fluids is not an easy task. ctDNA fragments present a short half-life, and there are no cut-off values to discriminate high and low ctDNA concentrations. Here, we discuss the use of ctDNA as a cancer biomarker, the main methodologies, the inherent difficulties, and the clinical predictive value of ctDNA.

show abstract

Section: Tumors With Higher Quantities Of Ctdna In the Patient´s Bloodmentioning

confidence: 99%

ctDNA as a Cancer Biomarker: A Broad Overview

Pessôa

Heringer²,

Ferrer

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Prostate cancer (PCa) is one of the most common cancers amongst men worldwide[ 53 , 54 ]. Like many other cancers, PCa management is plagued with the possibility of metastasis, therapy resistance, and poor diagnostic and prognostic biomarkers for screening[ 54 ].…”

Section: Circular Rna In Prostate Cancermentioning

confidence: 99%

Circular RNA and its potential as prostate cancer biomarkers

Tucker¹,

Zheng²,

Zhang³

et al. 2020

WJCO

View full text Add to dashboard Cite

Advancing knowledge of the transcriptome has revealed that circular RNAs (circRNAs) are widely expressed and evolutionarily conserved molecules that may serve relevant biological roles. More interesting is the accumulating evidence which demonstrates the implication of circRNAs in diseases, especially cancers. This revelation has helped to form the rationale for many studies exploring their utility as clinical biomarkers. CircRNAs are highly stable due to their unique structures, exhibit some tissue specificity, and are enriched in exosomes, which facilitate their detection in a range of body fluids. These properties make circRNAs ideal candidates for biomarker development in many diseases. This review will outline the discovery, biogenesis, and proposed functions of circRNAs.

show abstract

“…To overcome these challenges, new biomarkers with higher sensitivity and specificity are under intensive research. A special focus has been put on liquid biopsy biomarkers, especially in the blood due to their minimal invasiveness and fast real-time analysis [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia

Abramović

Vrhovec

Škara

et al. 2021

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the most commonly diagnosed neoplasm among men. Since it often resembles benign prostate hyperplasia (BPH), biomarkers with a higher differential value than PSA are required. Epigenetic biomarkers in liquid biopsies, especially miRNA, could address this challenge. The absolute expression of miR-375-3p, miR-182-5p, miR-21-5p, and miR-148a-3p were quantified in blood plasma and seminal plasma of 65 PCa and 58 BPH patients by digital droplet PCR. The sensitivity and specificity of these microRNAs were determined using ROC curve analysis. The higher expression of miR-182-5p and miR-375-3p in the blood plasma of PCa patients was statistically significant as compared to BPH (p = 0.0363 and 0.0226, respectively). Their combination achieved a specificity of 90.2% for predicting positive or negative biopsy results, while PSA cut-off of 4 µg/L performed with only 1.7% specificity. In seminal plasma, miR-375-3p, miR-182-5p, and miR-21-5p showed a statistically significantly higher expression in PCa patients with PSA >10 µg/L compared to ones with PSA ≤10 µg/L. MiR-182-5p and miR-375-3p in blood plasma show higher performance than PSA in discriminating PCa from BPH. Seminal plasma requires further investigation as it represents an obvious source for PCa biomarker identification.

show abstract

Liquid Biopsy Potential Biomarkers in Prostate Cancer

Cited by 11 publications

References 111 publications

ctDNA as a Cancer Biomarker: A Broad Overview

ctDNA as a Cancer Biomarker: A Broad Overview

Circular RNA and its potential as prostate cancer biomarkers

MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia

Contact Info

Product

Resources

About